Shanghai Junshi Biosciences Co.

Shanghai Junshi Biosciences Co.

Shanghai Junshi Biosciences, founded in 2012, is a Chinese biotechnology company led by chairman Feng Li and general manager Jun Du. The firm focuses on research, development, and commercialization of monoclonal antibodies and other biologic drugs, with a pipeline spanning oncology, autoimmune, and infectious disease indications. The company's core strategy centers on discovering and developing first-in-class and best-in-class biologics. Key assets include toripalimab, a PD-1 inhibitor approved in China for multiple cancers including melanoma and nasopharyngeal carcinoma, and a pipeline of candidates targeting immuno-oncology and inflammation. The firm also engages in partnerships with global biotech companies for co-development and licensing. Shanghai Junshi Biosciences employs over 1,000 people across its Shanghai headquarters and research facilities. The company went public on the Hong Kong Stock Exchange in 2018 and on the Shanghai STAR Market in 2020. Recent activity includes ongoing clinical trials and regulatory filings for toripalimab in the US and Europe (per SEC filings, 2023). The firm's structural differentiator is its position as a leading Chinese biotech with a globally validated PD-1 asset, navigating both domestic regulatory pathways and international expansion. Unlike many Chinese biotechs that rely solely on local development, Junshi partnered with Coherus BioSciences for US commercialization and seeks FDA approvals.